Novartis Targeting India For Natural Drug Ingredients
This article was originally published in PharmAsia News
India is a prime target for Novartis, the Swiss drug maker looking for biodiverse resources from which to produce drugs. The outgoing chairman of Novartis India said the parent company is looking at the seas, rain forests, fungi and micro-organisms that use natural ingredients to protect themselves. Peter Jager said a Novartis project in China is looking at fungi that contain an ingredient that fights cancer, and at a micro-organism in Thailand that grows on an insect. But Jager said India itself has a great potential for bioresources and is part of the Novartis research plan. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.